Eagle Pharmaceuticals, Inc. has announced the divestiture of the marketing authorization for Barhemsys in the U.S. to LXO Group in France. Barhemsys is the only FDA-approved treatment for Postoperative Nausea and Vomiting (PONV) and has been available in the U.S. since November 2020. The strategic divestiture is aimed at streamlining Eagle’s acute care business while maximizing value for shareholders. LXO Group plans to enhance its U.S. commercial capabilities through a direct hospital sales force for Barhemsys. Proceeds from the divestiture will support Eagle’s ongoing business operations.

Read more at GlobeNewswire: Eagle Pharmaceuticals Announces Divestiture of Barhemsys